(+/-)-6-(3-bromophenyl)-3,7-dioxa-bicyclo[4.1.0]heptane | 1174324-82-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氧环庚烷
• 英文名称: (+/-)-6-(3-bromophenyl)-3,7-dioxa-bicyclo[4.1.0]heptane
• 英文别名: 1,5:2,3-Dianhydro-3-C-(3-bromophenyl)-4-deoxypentitol；6-(3-bromophenyl)-3,7-dioxabicyclo[4.1.0]heptane
• CAS: 1174324-82-3
• 化学式: C₁₁H₁₁BrO₂
• 分子量: 255.111
• InChiKey: VQXJFSCJWYCQJC-UHFFFAOYSA-N

物化性质

• 沸点：
  335.6±37.0 °C(Predicted)
• 密度：
  1.570±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  21.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (+/-)-6-(3-bromophenyl)-3,7-dioxa-bicyclo[4.1.0]heptane 在 甲酸 、 sodium azide 、 氯化铵 、 一水合肼 作用下， 以 甲醇 、 水 为溶剂， 生成
  参考文献：
  名称：

  Diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxycycloalkylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against β-secretase-1 (BACE-1)

  摘要：

  A series of unique bicyclic aminooxazolines were synthesized and found to exhibit micromolar inhibition of beta-secretase-1 (BACE-1). The aminooxazolines were procured by an intramolecular diethylaminosulfur trifluoride (DAST)-mediated ring closure of a benzylic urea onto a secondary alcohol. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2013.07.136
• 作为产物：
  描述：

  4-(3-bromophenyl)-3,6-dihydro-2H-pyran 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 以90%的产率得到(+/-)-6-(3-bromophenyl)-3,7-dioxa-bicyclo[4.1.0]heptane
  参考文献：
  名称：

  Diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxycycloalkylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against β-secretase-1 (BACE-1)

  摘要：

  A series of unique bicyclic aminooxazolines were synthesized and found to exhibit micromolar inhibition of beta-secretase-1 (BACE-1). The aminooxazolines were procured by an intramolecular diethylaminosulfur trifluoride (DAST)-mediated ring closure of a benzylic urea onto a secondary alcohol. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2013.07.136

文献信息

• FUSED AMINODIHYDROTHIAZINE DERIVATIVES
  申请人：SUZUKI Yuichi

  公开号：US20090209755A1

  公开（公告）日：2009-08-20

  A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C 6-14 aryl group or the like, L is —NR e CO— or the like (wherein R e is a hydrogen atom or the like), Ring B is a C 6-14 aryl group or the like, X is a C 1-3 alkylene group or the like, Y is a single bond or the like, Z is a C 1-3 alkylene group or the like, R 1 and R 2 are each independently a hydrogen atom or the like, and R 3 , R 4 , R 5 and R 6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

  一个由以下通用公式表示的化合物：或其药用可接受的盐或其溶剂化物，其中环A是C6-14芳基或类似物，L是—NReCO—或类似物（其中Re是氢原子或类似物），环B是C6-14芳基或类似物，X是C1-3烷基烯基或类似物，Y是单键或类似物，Z是C1-3烷基烯基或类似物，R1和R2各自独立地是氢原子或类似物，而R3、R4、R5和R6各自独立地是氢原子、卤原子或类似物，具有Aβ产生抑制作用或BACE1抑制作用，并且可用作由Aβ引起的以阿尔茨海默型痴呆为特征的神经退行性疾病的预防或治疗剂。
• Fused aminodihydrothiazine derivatives
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US08158620B2

  公开（公告）日：2012-04-17

  A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

  该化合物的普遍式表示为：或其药学上可接受的盐或溶剂，其中环A为C6-14芳基或类似物，L为—NReCO—或类似物（其中Re为氢原子或类似物），环B为C6-14芳基或类似物，X为C1-3烷基或类似物，Y为单键或类似物，Z为C1-3烷基或类似物，R1和R2各自独立地为氢原子或类似物，而R3、R4、R5和R6各自独立地为氢原子、卤素原子或类似物。该化合物具有Aβ产生抑制作用或BACE1抑制作用，并可用作预防或治疗由Aβ引起的神经退行性疾病，如阿尔茨海默型痴呆症的药物。
• CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE
  申请人：Suzuki Yuichi

  公开号：US20100317850A1

  公开（公告）日：2010-12-16

  Disclosed is a compound represented by General formula (I), a pharmaceutically acceptable salt thereof, or a solvate of the compound or the pharmaceutically acceptable salt, which has an inhibitory activity of the production of Aβ or a BACE1-inhibiting activity, and is therefore useful as a prophylactic or therapeutic agent for Aβ-induced neurodegenerative diseases typified by Alzheimer-type dementia. Wherein the ring A represents a C 6-14 aryl group or the like; L represents —NR e CO— [wherein R e represents a hydrogen atom or the like] or the like; the ring B represents a C 6-14 aryl group or the like; X represents a C 1-3 alkylene group or the like; Y represents a single bond or the like; Z represents a C 1-3 alkylene group or the like; R 1 and R 2 independently represent a hydrogen atom or the like; and R 3 , R 4 , R 5 and R 6 independently represent a hydrogen atom, a halogen atom or the like.

  本发明涉及一种由通式（I）表示的化合物，其药学上可接受的盐或该化合物或药学上可接受的盐的溶剂，该化合物具有抑制Aβ产生或BACE1抑制活性，因此可用作治疗由阿尔茨海默病等Aβ诱导的神经退行性疾病的预防或治疗剂。其中，环A表示C6-14芳基或类似物；L表示—NReCO—[其中Re表示氢原子或类似物]或类似物；环B表示C6-14芳基或类似物；X表示C1-3烷基或类似物；Y表示单键或类似物；Z表示C1-3烷基或类似物；R1和R2独立地表示氢原子或类似物；而R3、R4、R5和R6独立地表示氢原子、卤素原子或类似物。
• US8158620B2
  申请人：——

  公开号：US8158620B2

  公开（公告）日：2012-04-17
• US8946210B2
  申请人：——

  公开号：US8946210B2

  公开（公告）日：2015-02-03